PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
Propanc Biopharma, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.32−0.03 (-7.31%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Propanc Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Market Cap | $2.01M | $197.05M |
| Enterprise Value | $1.17M | $106.56M |
| PB Ratio | 0.21 | 2.14 |
| P/TBV Ratio | 0.21 | 2.46 |
Income (trailing twelve months)
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Operating Income | -$18.19M | -$21.44M |
| Pretax Income | -$18.86M | -$14.45M |
| Net Income | -$18.86M | -$22.46M |
| EBITDA | -$18.19M | -$16.91M |
Returns
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -161.9% | -53.1% |
| Return on Assets (ROA) | -116.4% | -41.0% |
| Return on Invested Capital (ROIC) | -127.9% | -32.0% |
| Return on Capital Employed (ROCE) | -192.9% | -37.8% |
Balance sheet
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $832.01K | $62.42M |
| Net Cash (Debt) | $832.01K | $15.68M |
| Net Cash Per Share | $0.13 | $0.65 |
| Equity (Book Value) | $9.40M | $48.79M |
| Book Value Per Share | $1.48 | $1.36 |
| Tangible Book Value | $9.40M | $23.06M |
| Working Capital | $5.19M | $75.77M |
Financial position
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Current Ratio | 2.55 | 3.30 |
| Quick Ratio | 0.25 | 2.39 |
| Interest Coverage | -42.24 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.68M | -$12.35M |
| Capital Expenditures | -$4.93K | -$1.06M |
| Free Cash Flow | -$5.69M | -$20.28M |
| FCF Per Share | -$0.90 | -$0.41 |
Efficiency
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Profits Per Employee | -$9.43M | -$732.08K |
| Employee Count | 2 | 73 |
Dividends and yields
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -939.9% | -21.2% |
| FCF Yield | -283.4% | -7.64% |
| Buyback Yield | -165.1% | -0.58% |
| Shareholder Yield | -165.1% | 0.00% |
Shares
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 6,331,120 | 59,128,900 |
| Shares Change (QoQ) | -84.9% | 0.54% |
| Float | 6,331,120 | 48,744,500 |
| Shares Held by Insiders | 0.00% | 11.8% |
| Shares Held by Institutions | 0.76% | 59.4% |
Scores
| Measure | Propanc Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | -19.68 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Propanc Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.